4DMedical is a global leader in respiratory and cardiopulmonary software imaging using advanced technology and AI. It offers non-invasive, regional and lobar quantitative lung function analysis to enhance diagnosis of conditions like unexplained dyspnea, asthma, COPD, cystic fibrosis, and ILD. The company also provides low-dose lung health screening with customized smoking cessation tools for physicians to support their patients.
View the entire 4DMedical portfolio.
Friday, May 16 5:00–8:00pm
Saturday, May 17 7:00am–6:00pm
True Innovation.
4DMedical poster presentations showcase current and upcoming groundbreaking innovations:
Sunday, May 18–Tuesday May 20
10:30am–3:30pm, Booth 1827
“CT:VQ™: Transforming Regional Lung Function Assessment Through non-contrast CT-Based Ventilation/Perfusion Imaging“
CT:VQ™ converts standard (non-contrast) CT scans into high-quality ventilation and perfusion datasets, comparable to SPECT V/Q studies, without nuclear imaging or tracers. It fills a critical healthcare gap by using prevalent CT infrastructure, enhancing access, efficiency, and patient safety. CT:VQ™ supports major clinical needs, like pulmonary hypertension and lung cancer planning, promising a new standard in lung function assessment and broad adoption.
Speaker:
Prof. Andreas Fouras, CEO
“Advancements in IPF Diagnosis: Accelerating Accurate Detection with IQ-UIP™“
IQ-UIP™ by 4DMedical is FDA-cleared software utilizing Deep Convolutional Neural Networks to identify Usual Interstitial Pneumonia Patterns (UIP) on thoracic HRCT scans, associated with IPF. A critical lung disease, IPF is often misdiagnosed as COPD, with rates over 50%. Validated on 800+ scans, IQ-UIP achieved a 0.96 ROC-AUC, helping expedite ILD specialist referrals to improve patient outcomes.
Speaker:
Jonathan Chung, MD
IQ-UIP™—A New Approach to UIP Identification for IPF Management
Recognized as an FDA “Breakthrough Device” advancing early detection and intervention, IQ-UIP is innovative software that uses deep learning to accurately classify Usual Interstitial Pneumonia (UIP) and predict patient survival. Its performance matches that of expert CT readers. IQ-UIP integrates with inspiratory CT scans to provide instant analysis, significantly improving the efficiency of UIP identification. FDA-cleared in 2024, IQ-UIP sets a new benchmark in pulmonary diagnostics.
As COPD continues to grow as a global health burden—predicted by the World Health Organization (WHO) to become the third leading cause of death by 2030—innovative AI-driven medical imaging technologies are rapidly advancing diagnosis, staging, and treatment. In a recent Radiology Today article, “Breathing Room,” writer Beth W. Orenstein explores how clinicians are increasingly relying on advanced CT imaging solutions that overcome the limitations of traditional lung function testing methods such as spirometry, which can be uncomfortable and challenging for patients, particularly elderly and those with impaired lung capacity.
“Novel Machine Learning Algorithm Predicts All-cause Mortality in the National Lung Screening Trial”
The study, presented at ATS 2024, introduces a novel machine learning algorithm designed to predict all-cause mortality among participants in the National Lung Screening Trial. This algorithm leverages a comprehensive set of variables, including imaging data and clinical information, to enhance predictive accuracy. By integrating these diverse data sources, the algorithm provides a robust tool for stratifying patient risk, potentially guiding clinical decision-making and optimizing patient management.
Population Health Screening—Identifying and Re-engaging At-risk Patients
Emphysema and COPD are underdiagnosed in up to 50% of patients, and often not identified until advanced stages. For these patients, options like Bronchoscopic Lung Volume Reduction (BLVR) or Lung Volume Reduction Surgery (LVRS) can have a significantly positive impact on a patient’s quality of life.
B4 Symptoms, in collaboration with Lahey Hospital and Medical Center, a B4-sponsored pilot site, initiated a comprehensive screening program using 4DMedical’s advanced imaging analysis software, based on Imbio Technology. This program aims to identify patients who could benefit from BLVR and LVRS therapies for advanced emphysema.
